Xcout Intel
AstronauTx competitors & alternatives
The 12 closest competitors and alternatives to AstronauTx among biotechnology companies — ranked by similarity to what AstronauTx actually does, not by market-cap band.
Subscribe to see AstronauTx’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About AstronauTx
AstronauTx is a clinical-stage biotechnology company headquartered in London, United Kingdom. Founded in 2019, the firm develops novel small-molecule drugs aimed at treating neurodegenerative conditions such as Alzheimer's disease by targeting glial cell dysfunction.
Top 12 AstronauTx competitors
Ranked by semantic similarity — how close each company is to AstronauTx by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Axonis Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts, focused on discovering and developing novel treatments for neurological conditions and spinal cord injuries. Founded in 2019, the company advances therapeutic candidates through its proprietary research platform.
Similar biotechnology company
FoldLogic Bio is a clinical-stage biotechnology company developing targeted immunotherapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Multiple System Atrophy. The company focuses on modulating the central nervous system's immune responses, specifically targeting microglial activity, alpha-synuclein, and TREM2 to halt disease progression.
Similar biotechnology company
Vigil Neuroscience is a biotechnology company headquartered in Massachusetts that harnesses the power of microglia for the treatment of neurodegenerative diseases.
Similar biotechnology company
AviadoBio is a biotechnology research company formed on pioneering research from King's College London and the UK Dementia Research Institute. Headquartered in London, the company focuses on therapeutic advancements.
Similar biotechnology company
Arkuda Therapeutics is a biotechnology company developing small-molecule treatments for neurodegenerative diseases, with a focus on restoring lysosomal function and addressing progranulin-related disease biology. Its programs are aimed particularly at patients with frontotemporal dementia and other disorders involving lysosomal dysfunction.
Similar biotechnology company
Alzheon, Inc. is a clinical-stage biopharmaceutical company headquartered in Framingham, Massachusetts. Founded in 2013, the company is dedicated to developing a broad portfolio of investigational therapeutic products for neurodegenerative disorders, including Alzheimer's disease. Its research centers on advancing disease-modifying treatments for patients with cognitive decline.
Similar biotechnology company
Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to creating innovative neuroprotection therapies for traumatic brain injuries, strokes, and concussions. It is headquartered in Groton, Connecticut.
Similar biotechnology company
Muna Therapeutics is a privately held biopharmaceutical company founded in 2020 with headquarters in Copenhagen, Denmark, and operations in Leuven. The company discovers and develops novel therapies aimed at slowing or stopping devastating neurodegenerative diseases like Alzheimer's and Parkinson's.
Life Sciences
EXCIVA GmbH is a privately held biotechnology company established in 2016 in Heidelberg, Germany, focused on developing clinical-stage therapeutics to improve quality of life and treat Alzheimer's disease.
Biotech
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, including neuropsychiatric and neurodegenerative disorders. It uses neuroscience, data science, and biomarkers to identify and advance treatments for patients with these conditions.
Similar biotechnology company
Asceneuron is a biotechnology research company founded in 2012 and headquartered in Eysins, Switzerland, focusing on the discovery and development of therapeutics for neurodegenerative disorders.
Biotech
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of AstronauTx and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for AstronauTxand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →